PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes. The aim of this study was to demonstrate the contrast in risk factors for cardiovascular disease incidence and mortality in low, medium and high income countries.

This study included 155245 patients  from 628 cities in 17 countries over 5 continents. Individual risk was calculated using the INTERHEART risk score that takes into account the age, sex, smoking, diabetes, hypertension, family history of cardiovascular disease, heart rate, psychosocial assessment, diet and physical activity. The treatment used and preventive measures were also recorded.

The study showed that cardiovascular risk factors were higher in high-income countries and lower in low-income countries. Major cardiovascular diseases (heart attack, stroke, heart failure) occurs with an incidence of 4.3/1000 persons / year in high-income countries compared with 5.1 and 6.4 in countries of low and middle income, respectively. A fatal major cardiovascular disease has an incidence of 0.6/1000 persons / year in high-income countries compared with 1.7 and 3.8 in medium and low income respectively.

Conclusion:

Observing a greater overall risk in high-income countries but also lower mortality from major cardiovascular diseases,  highlights the importance of health systems (access, equity and efficiency) and not only the risk control factors. 

Salim%20Yusuf
Salim Yusuf
2013-09-02

Original title: PURE: Contrasting associations between risk-factor burden, CVD incidence, and mortality in high-, middle-, and low-income countries

More articles by this author

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were...

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque

Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces apoA-1  synthesis with favorable effect on HDL...

COMPARE: Losartan shows promising results in patients with Marfan syndrome

Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and sudden death. Current treatment recommends prophylactic surgery...

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.

Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...